Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

1.18
+0.05004.42%
Post-market: 1.200.0200+1.69%19:40 EDT
Volume:600.23K
Turnover:705.26K
Market Cap:83.93M
PE:-0.60
High:1.19
Open:1.15
Low:1.15
Close:1.13
Loading ...

Ventyx Biosciences highlights its 2025 pipeline strategy

TIPRANKS
·
14 Jan

Ventyx Biosciences: Phase 2 Trial of Vtx2735 in Participants With Recurrent Pericarditis Expected to Initiate in Jan

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor Portfolio

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences: Topline Data From Ongoing Phase 2 Biomarker Trial of Vtx3232 in Participants With Early Parkinson's Disease Expected in H1 2025

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

GlobeNewswire
·
14 Jan

We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Simply Wall St.
·
10 Jan

Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k

Simply Wall St.
·
14 Dec 2024

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
17 Nov 2024

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

GlobeNewswire
·
12 Nov 2024

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress

TIPRANKS
·
12 Nov 2024

Ventyx Biosciences Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Ventyx Biosciences (VTYX) Receives a Buy from LifeSci Capital

TIPRANKS
·
08 Nov 2024

Ventyx Biosciences : Oppenheimer Cuts Target Price to $9 From $10

THOMSON REUTERS
·
08 Nov 2024

Ventyx Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024

Ventyx Biosciences Q3 EPS $(0.50) Beats $(0.53) Estimate

Benzinga
·
08 Nov 2024

BRIEF-Ventyx Biosciences Q3 Net Income USD -35.249 Million

Reuters
·
08 Nov 2024

Ventyx Biosciences Inc: Cash Balance of $274.8M as of September 30, 2024 Expected to Fund Operations Into at Least H2 2026

THOMSON REUTERS
·
08 Nov 2024

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

GlobeNewswire
·
08 Nov 2024

Ventyx Biosciences Inc expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
02 Nov 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts

TipRanks
·
29 Oct 2024